Comparison of Oral versus Intravenous Proton Pump Inhibitors in Preventing Re-bleeding from Peptic Ulcer after Successful Endoscopic Therapy
Main Article Content
Keywords
Intravenous, Oral Proton Pump Inhibitors, Endoscopic Therapy, Re-bleeding, Peptic Ulcer.
Abstract
Peptic ulcer disease (PUD) consider a complex condition that can arise from a range of etiological factors. These include elevated dietary patterns, psychological strain, gastric acid secretion, Helicobacter pylori (H. pylori) infection, & prolonged administration of nonsteroidal anti-inflammatory medications. Bleeding, obstruction, & perforation continue to be the most encountered complications of PUD.
Objectives: To assess the efficacy of intravenous versus oral PPI in blocking rebleeding from peptic ulcers after successful endoscopic treatment.
Methods: The randomized controlled trials' inclusion criteria were to include: (i) each and every case who presented to the hospital with signs of ulcer bleeding, as demonstrated by haematemesis or melaena; (ii) an endoscopic procedure was carried out in order to halt the bleeding; (iii) patients were randomly assigned to receive PPIs either orally or intravenously; & (iv) a minimum of one of the subsequent outcomes—recurrent bleeding, surgical intervention, or mortality—was documented after the endoscopy procedure. Excluded were clinical trials that investigated cases involving malignant hemorrhage or patients who were already undergoing therapy with PPIs.
Results: throughout a one-month monitoring period, the involved research found no statistically significant variations among both groups Oral-Pan & IV-Pan) regarding the rates of re-endoscopy & re-bleeding, period of stay in hospital, operation, volume of blood transfusion, & mortality. Similar findings have been reported in several additional investigations.
Conclusion: The findings of our research indicate that cases with bleeding peptic ulcers and an elevated risk of re-bleeding may benefit from high-dose oral PPIs as an alternative to high-dose IV PPIs. The increased cost & accessibility of oral PPIs contribute to their considerably reduced cost.
References
2. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995;311:222–6.
3. Masoodi M, Saberifiroozi M. Etiology and outcome of acute gastrointestinal bleeding in iran: a review article. Middle East J Dig Dis. 2012;4:193–8.
4. Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology. 1992;102:139–48.
5. Hwang JH, Fisher DA, Ben-Menachem T, Chandrasekhara V, Chathadi K, Decker GA. et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc. 2012;75:1132–8.
6. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. 2009;7:33–47.
7. Marmo R, Rotondano G, Piscopo R, Bianco MA, D’Angella R, Cipolletta L. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am J Gastroenterol. 2007;102:279–89.
8. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74:38–43.
9. Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. World J Gastrointest Endosc. 2011;3:49–56.
10. Hartmann M, Ehrlich A, Fuder H, Luhmann R, Emeklibas S, Timmer W. et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther. 1998;12:1027–32.
11. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2–8.
12. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology. 2008;134:1836–41.
13. Sung JJ, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T, Peptic Ulcer Bleed Study Group*. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Annals of internal medicine. 2009 Apr 7;150(7):455-64.
14. Csiki E, Szabo H, Hanak L, Szakacs Z, Kiss S, Vörhendi N, Pecsi D, Hegyi E, Hegyi P, Eross B. Oral proton pump inhibitors may be as effective as intravenous in peptic ulcer bleeding: a systematic review and meta-analysis. Clinical and Translational Gastroenterology. 2021 Apr 1;12(4):e00341.
15. Mostaghni AA, Hashemi SA, Heydari ST. Comparison of oral and intravenous proton pump inhibitor on patients with high risk bleeding peptic ulcers: a prospective, randomized, controlled clinical trial. Iran Red Crescent Med J. 2011;13:458–63.
16. Toosi SM, Vahed AR, Maleki I, Bari Z. Comparison of oral versus intravenous proton pump inhibitors in preventing re-bleeding from peptic ulcer after successful endoscopic therapy. Middle East Journal of Digestive Diseases. 2018 Oct;10(4):236.
17. Liu N, Liu L, Zhang H, et al. Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. J Gastroenterol Hepatol 2012; 27: 1473–9.
18. Karim R, Hameed R, Ali K, Tahir A, Siddiqui A. Comparison of oral versus intravenous proton pump inhibitors in preventing re-bleeding from peptic ulcer after successful endoscopic therapy. Cureus. 2020 Jan 22;12(1).
19. Yen HH, Yang CW, Su WW, Soon MS, Wu SS, Lin HJ. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol. 2012;12:66.
20. Phulpoto JA, Bhatti ZA, shaikh A. Comparison of oral and intravenous proton pump inhibitor in patients with high risk bleeding peptic ulcers. Rawal Med J. 2013;38:7–10.
21. Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther. 2013;38:721–8.
22. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. InMayo Clinic Proceedings 2007 Mar 1 (Vol. 82, No. 3, pp. 286-296). Elsevier.
23. Mostaghni AA, Hashemi SA, Heydari ST. Comparison of oral and intravenous proton pump inhibitor on patients with high risk bleeding peptic ulcers: a prospective, randomized, controlled clinical trial. Iranian Red Crescent Medical Journal. 2011 Jul;13(7):458.
24. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. bmj. 2005 Mar 10;330(7491):568.
25. Zhang YS, Li Q, He BS, Liu R, Li ZJ. Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper gastrointestinal bleeding after endoscopy: a meta-analysis. World Journal of Gastroenterology: WJG. 2015 May 5;21(20):6341.
26. Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, Quitadamo M, Merla A, Fiorella S, Leandro G. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of metaanalyses. Official journal of the American College of Gastroenterology| ACG. 2005 Jan 1;100(1):207-19.
27. Masjedizadeh AR, Hajiani E, Alavinejad P, Hashemi SJ, Shayesteh AA, Jamshidian N. High dose versus low dose intravenous pantoprazole in bleeding peptic ulcer: a randomized clinical trial. Middle East Journal of Digestive Diseases. 2014 Jul;6(3):137.
28. Shavakhi A, Ataei S, Ataei M, Khodadostan M, Minakari MR. The comparison of oral omeprazole and intravenous pantoprazole effects in high risk upper gastrointestinal bleeding patients. Journal of Isfahan Medical School. 2008 Sep 22;26(90).
29. Tsai JJ, Hsu YC, Perng CL, Lin HJ. Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection. Br J Clin Pharmacol. 2009;67:326–32.
30. Siau K, Chapman W, Sharma N, Tripathi D, Iqbal T, Bhala N. Management of acute upper gastrointestinal bleeding: an update for the general physician. J R Coll Physicians Edinb. 2017;47:218–30.
31. Jiang M, Chen P, Gao Q. Systematic Review and Net-Work Meta-Analysis of Upper Gastrointestinal Hemorrhage Interventions. Cell Physiol Biochem. 2016;39:2477–91.
32. Sung JJ, Suen BY, Wu JC, Lau JY, Ching JY, Lee VW, Chiu PW, Tsoi KK, Chan FK. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Official journal of the American College of Gastroenterology| ACG. 2014 Jul 1;109(7):1005-10.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.